

Nishida K, Matsumoto Y, Kuroda J, Horiike S, Yokota S, Taniwaki M, Ohkawara Y.
Feasibility of modified MECP regimen as second-line chemotherapy for refractory or relapsed aggressive non-Hodgkin lymphoma. J Kyoto Pref Univ Med, 120:301-310, 2011

和文

- (12) 古林 勉、黒田純也、谷脇雅史. 多発性骨髄腫における骨リモデリングの正科学的バイオマーカー. 血液内科. 63(2), 265-270, 2011
- (13) 黒田純也. 慢性骨髄性白血病に対するチロシンキナーゼ阻害剤治療-知っておきたい基礎知識- BLOOD MASTER Vol. 8 「慢性骨髄性白血病」(前川 平 編)、大日本住友製薬、3-21、2011

2. 学会発表

- (14) 名越久朗、滝 智彦、花村一郎、仁田正和、大槻剛己、西田一弘、奥田恵子、小林 覚、山本未央、隄 康彦、古林 勉、松本洋典、堀池重夫、黒田純也、谷脇雅史. 8q24 異常を伴う多発性骨髄腫における PVT1 の関与および新規キメラ遺伝子 PVT-1-NBEA の同定. 第 36 回日本骨髄腫研究会総会. 平成 23 年 11 月 12 - 13 日 (2011) (東京)
- (15) Kuroda J, Kobayashi T, Kiyota M, Yamamoto M, Ohshiro M, Shimura Y, Nagoshi H, Nakayama R, Fuchida S, Uchiyama H, Matsumoto Y, Shimazaki C, Horiike S, Taniwaki M. Bortezomib overcomes high risk cytogenetic abnormalities in relapsed/refractory multiple myeloma. 第 36 回日本骨髄腫研究会総会. 平成 23 年 11 月 12 - 13 日 (2011) (東京)
- (16) 吉田 喬、松本守生、角南一貴、彼谷裕康、島崎千尋、黒田純也、瀧澤 淳、五十嵐忠彦、村山 徹、清水一之. 症候性多発性骨髄腫患者に対する自家末梢血幹細胞移植時の大量化学療法の有効性と安全性の検討. 第 36 回日本骨髄腫研究会総会. 平成 23 年 11 月 12 - 13 日 (2011) (東京)
- (17) 松村弥生、黒田純也、志村勇司、清田実希、山本未央、古林 勉、内山人二、松本洋典、堀池重夫、谷脇雅史. 自家移植後の早期再発と血球貪食症候群 (HPS) に対し同種幹細胞移植を施行した血管免疫芽球性 T 細胞リンパ腫 (AITL) 症例. 第 96 回近畿血液学地方会. 平成 23 年 11 月 12 日 (2011) (大阪)
- (18) Kobayashi T, Kuroda J, Fichida S, Tsutsumi Y, Yamashita M, Yamamoto M, Sasaki N, Ohshiro M, Mizutani S, Shimura Y, Kiyota M, Nakayama R, Chinen Y, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Taniwaki M. Roles of bortezomib as the induction for high dose therapy with autologous PBSCT in multiple myeloma. 第 73 回日本血液学会学術集会. 平成 23 年 10 月 14-16 日. (2011) (名古屋)
- (19) Kiyota M, Kobayashi T, Fichida S, Yamamoto M, Ohshiro M, Shimura Y, Nagoshi H, Sasaki N, Nakayama R, Sakamoto N, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Kuroda J, Taniwaki M. Bortezomib overcomes high risk cytogenetic abnormalities in relapsed/refractory multiple myeloma. 第 73 回日本血液学会学術集会. 平成 23 年 10 月 14-16 日. (2011) (名古屋)
- (20) Nakayama R, Matsumoto Y, Chinen Y, Kiyota M, Kobayashi S, Nagoshi H, Mizutani S, Shimura Y, Ohshiro M, Sasaki N, Yamamoto M, Yamashita M, Tsutsumi Y, Kobayashi T, Shimura K, Kaneko H, Kuroda J, Uchiyama H, Inaba T, Nishida K, Horiike S, Yokota S, Yanagisawa A, Taniwaki M. Analysis of B-cell clonality and chromosomal abnormalities in IgG4-related disease. 第 73 回日本血液学会学術集会. 平成 23 年 10 月 14-16 日. (2011) (名古屋)
- (21) Kobayashi S, Taki T, Tsutsumi Y, Nagoshi H, Matsumoto Y, Kuroda J, Horiike S, Nishida K, Taniwaki M. Analysis of BACH2-related genes in B-cell malignancies. 第 73 回日本血液学会学術集会. 平成 23 年 10 月 14-16 日. (2011) (名古屋)
- (22) Sasaki N, Kuroda J, Nagoshi H, Yamamoto M, Kobayashi S, Tsutsumi Y, Shimura Y, Nakayama R, Kobayashi T, Matsumoto Y, Taki T, Nishida K, Horiike S, Akao Y, Taniwaki M

- Bcl-2 is a better target compared to c-Myc in novel DLBCL cell lines with Bcl-2/c-Myc overexpression. 第 73 回日本血液学会学術集会. 平成 23 年 10 月 14-16 日. (2011) (名古屋)
- (23) Horiike S, Shimura Y, Matsumoto Y, Ohshiro M, Yamamoto M, Mizutani S, Kobayashi T, Uchiyama H, Kuroda J, Taniwaki M. Rapid cytogenetic and molecular responses in newly diagnosed CML-CP patients treated with dasatinib. 第 73 回日本血液学会学術集会. 平成 23 年 10 月 14-16 日. (2011) (名古屋)
- (24) Shimura Y, Horiike S, Kiyota M, Ohshiro M, Yamamoto M, Kobayashi T, Uchiyama H, Matsumoto Y, Kuroda J, Taniwaki M. Third line TKI therapy for two CML patients showing KD mutation and resistance to prior 2 TKIs. 第 73 回日本血液学会学術集会. 平成 23 年 10 月 14-16 日. (2011) (名古屋)
- (25) Tsutsumi Y, Chinen Y, Nakayama R, Kiyota M, Mizutani S, Shimura Y, Ohshiro M, Yamamoto M, Kobayashi S, Nagoshi H, Taki T, Kobayashi T, Uchiyama H, Matsumoto Y, Kuroda J, Horiike S, Taniwaki M. Genome array and spectral karyotyping analysis of highly aggressive B-cell leukemia/lymphomas. 第 73 回日本血液学会学術集会. 平成 23 年 10 月 14-16 日. (2011) (名古屋)
- (26) Yamamoto M, Kuroda J, Ashihara E, Nagoshi H, Kobayashi T, Matsumoto Y, Sasaki N, Shimura Y, Kiyota M, Nakayama R, Uoshima N, Kobayashi Y, Taki T, Horiike S, Maekawa T, Taniwaki M. Galectin-3 induced by leukemia microenvironment promotes drug resistance and BM lodgement in CML. 第 73 回日本血液学会学術集会. 平成 23 年 10 月 14-16 日. (2011) (名古屋)
- (27) 岡部雅弘、山口博樹、臼杵憲祐、小林 裕、黒田純也、田近賢二、五味聖二、三田村佳勇、小坂文子、猪口孝一、檀 和夫. 本邦の骨髓増殖性疾患における JAK2 遺伝子ハプロタイプの解析. 第 73 回日本血液学会学術集会. 平成 23 年 10 月 14-16 日. (2011) (名古屋)
- (28) Ohshiro M, Kuroda J, Kobayashi Y, Uoshima N, Kaneko H, Shimazaki C, Kobayashi T, Uchiyama H, Matsumoto Y, Horiike S, Taniwaki M. ADAMTS13 can predict the outcome of DIC using recombinant thrombomodulin in hematologic malignancies. 第 73 回日本血液学会学術集会. 平成 23 年 10 月 14-16 日. (2011) (名古屋)
- (29) 黒田純也、古林 勉、山本未央、赤尾幸博. Bcl-2 と c-Myc を過剰発現する新規 B 細胞性リンパ腫細胞株 2 株における Bcl-2 と c-Myc の分子標的としての意義. 日本がん分子標的治療学会第 15 回学術集会. 平成 23 年 6 月 22-23 日. (2011) (東京)
- (30) 古林 勉、黒田純也、隄 康彦、山下美穂子、山本未央、大城宗生、内山人二、松本洋典、堀池重夫、谷脇雅史. シクロスポリンが著効した化学療法抵抗性血管免疫芽球性 T 細胞リンパ腫. 第 95 回近畿血液学地方会. 平成 23 年 6 月 18 日 (2011) (兵庫)
- (31) Nagoshi H, Taki T, Hanamura I, Nitta M, Otsuki T, Nishida K, Okuda K, Sakamoto N, Kobayashi S, Yamamoto M, Tsutsumi Y, Kobayashi T, Matsumoto Y, Horiike S, Kuroda J, Taniwaki T. Frequent Involvement of PVT1 in Multiple Myeloma Carrying 8q24 Rearrangement and Identification of Novel PVT1-NBEA Chimeric Gene. The American Society of Hematology 53rd Annual Meeting and Exposition (San Diego, USA) 平成 23 年 12 月 11 日 (2011)
- (32) Kuroda J, Yamamoto M, Ashihara E, Nagoshi H, Kobayashi T, Matsumoto Y, Sasaki N, Shimura Y, Kiyota M, Nakayama R, Horiike S, Maekawa T, Taniwaki M. Leukemia Microenvironment-Specific Galectin-3 Expression of Leukemic Cells Promotes Malignant Niche Formation and Bone Marrow Lodgment of Leukemic Cells in Chronic Myelogenous Leukemia. The American Society of Hematology 53rd Annual Meeting and Exposition (San Diego, USA) 平成 23 年 12 月 11 日 (2011)
- (33) Yamamoto M, Kuroda J, Kobayashi T,

Sasaki N, Nagoshi H, Shimura Y, Kiyota M, Nakayama R, Horiike S, Ashihara E, Akaji K, Taniwaki M. Galectin-3 Is the Molecular Target for Overcoming Multidrug Resistance Due to the Cell Protection by Bone Marrow Leukemia Microenvironment in Chronic Myeloid Leukemia. The American Society of Hematology 53rd Annual Meeting and Exposition (San Diego, USA) 平成 23 年 12 月 11 日 (2011)

3. その他
なし

(34) 谷山暢子, 朴 恩榮, 中村考志, 和田小依里, 佐藤健司, 中山理裕子, 黒田純也, 谷脇雅史. ヒト白血病細胞への Galectin-3 遺伝子導入による培地中のタンパク質の組成変化. 第 1 回 4 大学連携研究フォーラム. 平成 23 年 12 月 9 日 (2011) (京都)

(35) Kaneko H, Shimura K, Nishida K, Ohkawara Y, Matsumoto Y, Kuroda J, Horiike S, Yokota S, Taniwaki M. Clinical outcomes of gastrointestinal tract B-cell lymphoma. 第 73 回日本血液学会学術集会. 平成 23 年 10 月 14-16 日. (2011) (名古屋)

(36) Uchiyama H, Chinen Y, Nakayama R, Kiyota M, Mizutani S, Shimura Y, Ohshiro M, Yamamoto M, Tsutsumi Y, Yamashita M, Kobayashi T, Matsumoto Y, Kuroda J, Inaba T, Horiike S, Taniwaki M. Rasburicase for the management of hyperuricemia on patients with hematologic malignancies. 第 73 回日本血液学会学術集会. 平成 23 年 10 月 14-16 日. (2011) (名古屋)

(37) 山本未央, 黒田純也, 芦原英司, 古林 勉, 前川 平. 慢性骨髄性白血病の病態形成と治療抵抗性獲得における骨髄腫瘍環境誘導性 Galectin-3 の重要性. 日本がん分子標的治療学会第 15 回学術集会. 平成 23 年 6 月 22-23 日. (2011) (東京)

H. 知的財産権の出願・登録状況
(予定を含む)

1. 特許取得
なし
2. 実用新案登録
なし

III. 研究成果の刊行一覧

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
矢野寛樹 飯田真介	26. マクログロブリン血症	日本血液学会	血液専門医テキスト	南江堂	東京	2011	322-326
飯田真介 矢野寛樹	27. 多発性骨髄腫 血液専門医テキスト	日本血液学会	血液専門医テキスト	南江堂	東京	2011	327-335
稲垣淳、 飯田真介	7. 多発性骨髄腫および類縁疾患 4. 移植非適応高齢者多発性骨髄腫の治療	木崎昌弘	白血病 リンパ腫 骨髄腫 今日の診断と治療 第4版	中外医学社	東京	2011	485-496
矢野寛樹 飯田真介	VII. 多発性骨髄腫	直江知樹	現場で役立つ血液腫瘍治療プロトコール集 改訂版	医薬ジャーナル社	大阪	2011	164-179
飯田真介	10. 血液疾患 多発性骨髄腫	山口徹、北原光夫、福井次矢	今日の治療指針 Today's Therapy 2012	医学書院	東京	2012	591-593
島田和之 木下朝博	血管内大細胞型B細胞リンパ腫の治療	木崎昌弘	白血病 リンパ腫 骨髄腫 今日の診断と治療 第4版	中外医学社	東京	2011	413-418
満間綾子 木下朝博	中悪性非ホジキンリンパ腫	直江知樹	現場で役立つ血液腫瘍治療プロトコール集	医薬ジャーナル社	東京	2011	124-135
木下朝博	悪性リンパ腫	日本在宅医療学会	医師・看護師・薬剤師のための外来化学療法実践セミナー in 名古屋2011	癌と化学療法社	東京	2011	10-18
木下朝博	抗CD30抗体によるホジキンリンパ腫と未分化大細胞型リンパ腫の治療	高久史麿 小澤敬也 坂田洋一 金倉 譲 小島勢二	Annual Review 血液2012	中外医学社1	東京	2011	159-163

黒田純也	慢性骨髄性白血病 に対するチロシン キナーゼ阻害剤治 療-知っておきたい 基礎知識	前川 平	BLOOD MASTER Vol.8 「慢性骨 髄性白血病」	大日本住 友製薬	京都	2011	3-21
------	---	------	--------------------------------------	-------------	----	------	------

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Shimizu K, <u>Murakami H</u> , Sawamura M, Hattori Y, Okamoto S, Miwa A, Sugiura I, Shimazaki C, Taniwaki M, Ishida T, Hayashi T, Kosugi H, Yuge M, <u>Iida S</u> , Ishida T, Sunami K, Asaoku H, Sakai A, Abe A, Takagi T	Efficacy of long-term treatment with low-dose thalidomide for patients with relapsed/refractory multiple myeloma.	Int J Clin Med	2	570-575	2011
Hosen N, Ichihara H, Mugitani A, Aoyama Y, Fukuda Y, Kishida S, Matsuoka Y, Nakajima H, Kawakami M, Yamagami T, Fujii S, Tamaki H, Nakano T, Nishida S, Tsuboi A, <u>Iida S</u> , Hino M, Oka Y, Oji Y, Sugiyama H	CD48 as a novel molecular target for antibody therapy in multiple myeloma.	Br J Haematol	156	213-224	2012
Yoshizawa S, Ohyashiki J, Suzuki K, <u>Iida S</u> , Ohyashiki K	Down-regulated plasma miR-92a levels have clinical impact in mu ltiple myeloma and re lated disorders.	Blood Cancer J	2	In press	2012
Grass S, <u>Iida S</u> , Wikowicz A, Preuss KD, Inagaki A, Shimizu K, Ziepert M, Ueda R, Pfreundschuh M.	Risk of Japanese carr iers of hyperphosphor ylated paratarg-7, th e first autosomal-dom inantly inherited ris k factor for hemato logical neoplasms, to d evelop MGUS and multi ple myeloma.	Cancer Sci	102	565-568	2011
Chou T, Tobinai K, Uike N, Asakawa T, Saito I, Fukuda H, Mizoroki F, Ando K, <u>Iida S</u> , Ueda R, Tsukasaki K, Hotta T.	Melphalan-prednisolon e and vincristine-dox orubicin-dexamethason e chemotherapy follow ed by prednisolone/in terferone maintenance therapy for multiple myeloma: Japan Clini cal Oncology Group St udy JCOG0112.	Jpn J Clin Oncol	41	586-589	2011

Nakano A, Abe M, Oda A, Amou H, Hiasa M, Nakamura S, Miki H, Harada T, Fujii S, Kagawa K, Takeuchi K, <u>Watanabe T</u> , Ozaki S, Matsumoto T.	Delayed treatment with vitamin C and N-acetylcysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib.	Int J Hematol	93	727-735	2011
Ogura M, Ando K, Taniwaki M, <u>Watanabe T</u> , Uchida T, <u>Ohmachi K</u> , Matsumoto Y, Tobinai K	Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma	Cancer Sci	102	1687-92	2011
Nagai H, Ogura M, Kusumoto S, Takahashi N, Yamaguchi M, Takayama N, <u>Kinoshita T</u> , Motoji T, Ohyashiki K, Kosugi H, Matsuda S, Ohnishi K, <u>Omachi K</u> , Hotta T	Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma	Eur J Haematol	86	117-23	2011
Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T, Oshima R, Tanimoto M, Iwasaki T, Isoda A, Sakai A, Kobayashi H, Kitamura K, Matsue K, Taniwaki M, Tamashima S, Saburi Y, Masunari T, Naoe T, Nakamura S, <u>Kinoshita T</u> .	Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan	Blood	Prepublished online Feb. 2		2012
<u>Watanabe T</u> , Tobinai K, Shibata T, Tsuakasaki K, Morishima Y, Maseki N, <u>Kinoshita T</u> , Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Takeuchi K, Nawano S, Terauchi T, Hotta T.	Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG0203 trial	J Clin Oncol	29	3990-3998	2011
Miyazaki K, Yamaguchi M, Suzuki R, Kobayashi Y, Maeshima AM, Niitsu N, Ennishi D, Tamaru J-I, Ishizuka K, Kashimura M, Kagami Y, Sunami K, Yamane H, Nishikori M, Kosugi H, Yujiri T, Hyo R, Katayama N, <u>Kinoshita T</u> , Nakamura S.	CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab	Ann Oncol	22	1601-1607	2011

Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Tano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Oshima R, Hatta Y, Moriuchi Y, <u>Kinoshita T</u> , Yamamoto M, Numata A, Ishigatsubo Y, Takeuchi K.	Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era	Cancer Sci	103	245-251	2011
Tobinai K, Igarashi T, Itoh K, Kurosawa M, Nagai H, Hiraoka A, <u>Kinoshita T</u> , Uike N, Ogura M, Nawano S, Mori S, Ohashi Y.	Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study	Cancer Sci	102	1898-1705	2011
Yamashita Y, Kajiura D, Tang L, Hasegawa Y, <u>Kinoshita T</u> , Nakamura S, Akatsuka S, Toyokuni S, Mori N.	XCRI expression and biased VH gene usage are distinct features of diffuse large B-cell lymphoma initially manifesting in the bone marrow	Am J Clin Pathol	135	556-564	2011
Asano N, <u>Kinoshita T</u> , Tamaru J, Ohshima K, Yoshino T, Niitsu N, Tsukamoto N, Hirabayashi K, Izutsu K, Taniwaki M, Morishima Y, Nakamura S.	Cytotoxic molecule-positive classical Hodgkin's lymphoma: a clinicopathological comparison with cytotoxic molecule-positive peripheral T-cell lymphoma of not otherwise specified.	Hametologica	96	1636-1643	2011
Kumar SK, <u>Hata H</u> et al.	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study	Leukemia	26	149-157	2011
Kawano Y, Ueno S, Abe M, Kikukawa Y, Yuki H, Iyama K, Okuno Y, Mitsuya H, <u>Hata H</u> .	TRAIL produced from multiple myeloma cells is associated with osteolytic markers.	Oncology Rep	27	39-44	2011

Kaneko H, <u>Kuroda J</u> , et al.	Feasibility of modified MECP regimen as second-line chemotherapy for refractory or relapsed aggressive non-Hodgkin lymphoma	Journal of Kyoto Prefectural University of Medicine	120	301-310	2011
Sasaki N, <u>Kuroda J</u> , et al.	Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B cell lymphoma with concurrent Bcl-2 and c-Myc overexpression	Experimental Hematology	39	817-828	2011
Nagoshi H, <u>Kuroda J</u> , et al.	Cytogenetic and Molecular Abnormalities in Myelodysplastic Syndrome	Current Molecular Medicine	11	678-685	2011
Kobayashi T, <u>Kuroda J</u> , et al.	Successful treatment of chemotherapy-refractory angioimmunoblastic T-cell lymphoma with cyclosporin A	Acta Haematologica	127	10-15	2011
<u>Kuroda J</u> , Taniwaki M	Principles and current topics concerning management of tyrosine kinase inhibitor therapy for chronic myelogenous leukemia	Translational Medicine			In press
Ohshiro M, <u>Kuroda J</u> , et al.	ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin	American Journal of Hematology	87	116-119	2012
Yao H, <u>Kuroda J</u> , et al.	AV-65, a novel Wnt/ β -catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model	Blood Cancer Journal			In press
Yamamoto-Sugitani M, <u>Kuroda J</u> , et al.	Galectin-3 induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia	Proceedings of the National Academy of Science of United States of America	108	17468-17473	2011

Chinen Y, <u>Kuroda J</u> , et al.	Intravascular B-cell lymphoma with hypercalcemia as the initial presentation.	International Journal of Hematology	94	567-570	2011
Kobayashi T, <u>Kuroda J</u> , et al.	Clinical studies of molecular targeted therapy for multiple myeloma	Translational Medicine			In press
Kaneko H, <u>Kuroda J</u> , et al.	Cytogenetic analysis of de novo CD5-positive diffuse large B-cell lymphoma.	Asia Pacific Journal of Clinical Oncology	7	346-350	2011
花村一朗、 <u>飯田真介</u>	多発性骨髄腫に対する新規治療薬の展望	血液内科	62	338-350	2011
稲垣宏、 <u>飯田真介</u>	染色体転座・遺伝子転座 - 悪性リンパ腫・多発性骨髄腫	病理と臨床	29	468-471	2011
花村一朗、 <u>飯田真介</u>	新規薬剤時代の多発性骨髄腫における造血幹細胞移植の動向	医学の歩み	240	409-417	2012
<u>飯田真介</u>	臨床血液学：今後の展望（2012年版）- リンパ系疾患 - 多発性骨髄腫	臨床血液	53	155-163	2012
矢野寛樹、 <u>飯田真介</u>	State of the Art 多発性骨髄腫	外来化学療法	2	15-20	2012
<u>渡辺 隆</u>	特集「多発性骨髄腫研究の最近の進歩」 ボルテゾミブによる末梢神経障害発症機構	血液内科	血液内科	科学評論社	東京
<u>渡辺隆</u> <u>岡本昌隆</u> <u>小椋美知則</u> <u>木下朝博</u> <u>永井宏和</u>	ホジキンリンパ腫診療の現在	Trends in Hematological Malignancies	Vol. 3 No. 1	8-13	2011
<u>大間知謙</u>	B細胞性リンパ腫治療の現状と新たな展開	臨床血液	63	20-25	2011
<u>木下朝博</u>	悪性リンパ腫—最近の診断と治療の進展	総合臨床	第60巻 3号	459-460	2011

小野田浩 木下朝博 谷田部恭	二次性形質細胞性白血病 の1例	血液フロンティア	Vol. 21 No. 10	5-10	2011
河野和、畑裕之	分子病態に基づく多発 性骨髄腫の治療戦略	血液内科	62	463-468	2011
畑裕之	再発難治性骨髄腫に対 する治療戦略	内科	108	252-255	2011
畑裕之	多発性骨髄腫に対する 新規治療薬開発の現状 と展望	臨床血液	52	603-608	2011
畑裕之	免疫調節薬による骨髄 腫治療	臨床血液	52	1485-1495	2011
古林勉、黒田純也、谷脇雅 史	多発性骨髄腫における骨 リモデリングの生化学的 バイオマーカー	血液内科	63	265-270	2011

IV. 研究成果の刊行物・別冊

ORIGINAL ARTICLE

Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders

S Yoshizawa¹, JH Ohyashiki², M Ohyashiki¹, T Umezū³, K Suzuki⁴, A Inagaki⁵, S Iida⁵ and K Ohyashiki^{1,3}

Recent studies have demonstrated that one-third of known microRNAs (miRNAs) are stably detectable in plasma. Therefore, we assessed plasma miRNAs to investigate the dynamics of oncomir 17-92a, which is highly expressed in multiple myeloma (MM) patients. The plasma miR-92a level in symptomatic MM patients was significantly downregulated compared with normal subjects ($P < 0.0001$), regardless of immunoglobulin subtypes or disease stage at diagnosis. In contrast, miR-92a levels in peripheral blood CD8⁺ or CD4⁺ cells from MM patients were lower than those of normal subjects, and the miR-92a levels of the cells tended to correlate with plasma miR-92a levels. The plasma miR-92a level in the complete remission group became normalized, whereas the partial response (PR) and very good PR groups did not reach the normal range. In smoldering MM, the plasma miR-92a level did not show a significant difference compared with normal subjects. Our findings suggest that measurement of the plasma miR-92a level in MM patients could be useful for initiation of chemotherapy and monitoring disease status, and the level may represent, in part, the T-cell immunity status of these patients.

Blood Cancer Journal (2012) 2, e53; doi:10.1038/bcj.2011.51; published online 20 January 2012

Keywords: multiple myeloma; plasma miR-92a; T lymphocytes;

INTRODUCTION

MicroRNAs (miRNAs) consist of approximately 18–22-nucleotide non-coding RNA molecules that regulate posttranscriptional gene expression by degradation or repression of mRNA molecules.^{1–3} Individual miRNAs can target multiple mRNAs and control transcription in approximately one-third of human genes. Recent studies have shown that these miRNAs are closely involved in cell differentiation, proliferation, apoptosis or oncogenesis.^{1–3} In various human cancer, there is evidence of the alteration of tumor tissue-specific miRNA.^{4–6} A 2008 study demonstrated that miRNAs stably exist in serum and plasma,^{7,8} and a recent advance revealed the presence of circulating miRNAs within lipoprotein (known as microvesicles), which may help to protect the miRNAs from RNase-dependent degradation.^{9,10} Moreover, some extracellular circulating miRNAs in blood plasma are independent of exosomes and are bound to Ago2 protein, resulting in strong nuclease/proteinase resistance,¹¹ thus indicating a possible role of circulating miRNAs in healthy subjects and disease condition.^{7,8} The biological relevance of circulating miRNAs remains unclear, although they may have an important role in cancer metastasis or neo-angiogenesis. Therefore, circulating miRNAs are thought to be possible diagnostic or prognostic biomarkers of human diseases.^{12–14}

It is well-known that multiple myeloma (MM) cells have a high expression level of the miR-17-92a cluster,¹⁵ whereas plasma miR-92a levels in acute lymphoid leukemia or non-Hodgkin's lymphoma are extremely downregulated.^{16–18} Downregulation of miRNAs, let-7a and miR-16 in myelodysplastic syndromes also has been reported, and their levels were significantly associated with progression-free survival and overall survival, suggesting that certain miRNAs in plasma can serve as noninvasive biomarker in

hematologic malignancies.¹⁹ To gain more insight into the clinical relevance of plasma miR-92a expression, we evaluated plasma miR-92a levels in MM patients at various phases and in patients with related disorders. In addition, we examined cellular miR-92a levels in circulating lymphocytes obtained from untreated MM patients and compared them with the plasma miR-92a level to ascertain the possible association between immunological condition and plasma miR-92a expression.

MATERIALS AND METHODS

Patients and samples

We evaluated peripheral blood obtained from 168 patients with monoclonal gammopathies: 138 with symptomatic MM, 8 with smoldering MM (SMM) and 22 with monoclonal gammopathy of undetermined significance (MGUS). The diagnosis of monoclonal gammopathy was based on the definition of the International Myeloma Working Group using the level of serum M-protein, proportion of plasma cells in bone marrow and the presence of end-organ damage.²⁰ At the time of plasma collection, the disease status of the 138 patients with symptomatic MM was as follows (Table 1): 62 newly diagnosed, 8 complete remission (CR), 11 very good partial response (VGPR), 15 partial response (PR), 14 stable disease and 28 progressive disease. None of the 62 newly diagnosed MM patients had del(13q) anomaly, where the miR-17-92a located, according to the standard cytogenetic technique. Of the eight SMM patients, two had received cytotoxic therapy because of an increase in M-protein (≥ 5 g/dl). No MGUS patients had received chemotherapy before plasma collection. We analyzed plasma from 113 normal individuals and isolated lymphocytes from 21 healthy volunteers as the control. These samples were handled similarly to those obtained from MM patients.

¹Department of Hematology, Tokyo Medical University, Tokyo, Japan; ²Institute of Medical Science, Tokyo Medical University, Tokyo, Japan; ³Department of Molecular Science, Tokyo Medical University, Tokyo, Japan; ⁴Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan and ⁵Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Correspondence: Professor K Ohyashiki, Department of Hematology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.

E-mail: ohyashik@r.ij4u.or.jp

Received 6 October 2011; revised 1 December 2011; accepted 5 December 2011

Table 1. Plasma miR-92a/miR-638 expression levels in monoclonal gammopathies

	Number of subjects	Median	Mean	Standard error	Minimum	Maximum	95% CI
Normal	113	1.244	1.388	0.06993	0.2154	3.58	1.249–1.527
Symptomatic MM at diagnosis	62	0.05202	0.1008	0.01899	0.000045	0.8586	0.06285–0.1388
<i>Myeloma subtype</i>							
Ig G	26	0.06107	0.121	0.03378	0.000045	0.8586	0.05146–0.1906
Ig A	12	0.1508	0.05435	0.1901	0.006992	3.127	0.3020–1.089
Ig D	3	0.1667	0.2353	0.1423	0.0304	0.5087	–0.3769–0.8475
Bence–Jones protein	14	0.03866	0.0973	0.04252	0.004289	0.6177	0.005448–0.1892
Non-secretory myeloma	4	0.06367	0.07089	0.02974	0.01013	0.1461	–0.02376–0.1655
Plasma cell leukemia	3	0.02628	0.03341	0.01985	0.003151	0.07081	–0.05201–0.1188
<i>Disease status of MM</i>							
Newly diagnosed	62	0.05202	0.1008	0.01899	0.000045	0.8586	0.06285–0.1388
CR	8	1.494	1.602	0.354	0.2285	3.643	0.7653–2.439
VGPR	11	0.2176	0.3591	0.09528	0.04138	1.028	0.1468–0.5714
PR	15	0.8179	0.7967	0.2018	0.1216	1.979	0.5409–1.052
Stable disease	14	0.3404	0.4251	0.2634	0.003508	0.9965	0.2479–0.6022
Progressive disease	28	0.06335	0.2018	0.04978	0.003319	0.8586	0.09962–0.3039
SMM	8	0.7943	1.188	0.4791	0.09087	5.242	0.3002–1.348
MGUS	22	0.4055	0.6403	0.1309	0.007652	2.428	0.3681–0.9124

Abbreviations: CI, confidence interval; CR, complete remission; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; PR, partial response; SMM, smoldering MM; VGPR, very good partial response. Disease status of multiple myeloma was categorized by International Myeloma Workshop Consensus criteria.²⁰

This study was approved by the institutional review board of Tokyo Medical University (no. 930, approved 24 June 2008). Written informed consent was obtained from all the participants prior to the collection of specimens according to the Declaration of Helsinki.

TaqMan low-density array screening

Total RNA was isolated with the mirVana PARIS kit (Ambion, Austin, TX, USA). Plasma samples from five patients or five healthy individuals were mixed evenly, and 500 µl of mixed plasma was diluted with 500 µl of binding solution. After a 5-min incubation, 1 µl of 1 nM ath-miR-159 (Hokkaido System Science, Hokkaido, Japan) was added to each aliquot, followed by vortexing for 30 s and incubation on ice for 10 min. Subsequent phenol extraction and filter cartridge work was performed according to the manufacturer's instructions. In all, 3 µl of RNA solution from the 50-µl elute was used as an input in each reverse transcription (RT) reaction. The RT reaction and pre-amplification step were set up according to the manufacturer's recommendations. miRNAs were reverse transcribed with the Megaplex Primer Pools (Human Pools A v2.1; Applied Biosystems, Foster City, CA, USA). RT reaction products from the plasma sample were further amplified with Megaplex PreAmp Primers (Primers A v2.1). The expression profile of the miRNAs was determined with the Human TaqMan miRNA Arrays A (Applied Biosystems). Quantitative RT-PCR was performed on an Applied Biosystems 7900HT thermocycler according to the manufacturer's recommended program. With the use of SDS2.2 software and DataAssist (Applied Biosystems), the expression of plasma miRNAs was calculated based on their Ct values normalized by those of ath-miR-159, which was spiked in each plasma sample.

miR-92a quantitative RT-PCR

Total RNA in cells was isolated with an miRNeasy Mini Kit (Qiagen, Germantown, MD, USA), and RNA in plasma was extracted as reported previously.^{17,18} miRNAs were quantified with TaqMan MicroRNA Assays (Applied Biosystems) with modification and miRNA-specific stem-loop primers (has-miR-92a, 000431; has-miR-638, 001582; Applied Biosystems), as we reported previously.^{17,18} The plasma miR-92a expression was normalized to miR-638 expression, and the cellular miR-92a expression levels were normalized to RNU6B (001093; Applied Biosystems). We have never detected U6B in a plasma sample, although U6B is commonly used as an internal standard for miRNA expression analysis in cells. To normalize

the expression level of miR-92a in plasma, we compared plasma miR-92a expression using an external standard, cel-miR-39 (Hokkaido System Science), as well as an internal standard, miR-638, which is stably detected in all samples. The results using miR-638 are compatible with those using cel-miR-39 (data not shown). We therefore used miR-638 as a reference in each plasma sample, as previously reported.^{17,18}

Lymphocyte separation

The CD4⁺ or CD8⁺ T-cell fractions were separated with an isolation kit for humans (Miltenyi Biotec, Bergisch Gladbach, Germany) and AutoMACS Pro Separator (Miltenyi Biotec), according to the supplier's instruction, and stored at –80 °C until use.

Statistical analysis

GraphPad 5.0 software (GraphPad Software Inc, San Diego, CA, USA) was used for statistical analysis. The Mann–Whitney test was used to determine statistical significance between two groups and one-way ANOVA for three or more groups. We also used the Chi-square test and Student's *t*-test, when appropriate. *P*-values < 0.05 were considered to indicate statistically significant differences.

RESULTS

Identification of differentially expressed plasma miRNAs in MM patients and healthy volunteers

Plasma miRNA expression was initially screened using the TaqMan low-density array system. Of the 381 miRNAs represented on the well plates, 331 miRNAs were not detected after the 35 PCR cycles. Among the remaining 50 miRNAs, upregulated and down-regulated miRNAs in MM plasma samples (expression level in the sample was 4-fold greater or lower than that of healthy volunteers) were selected. We then evaluated the rank order of expression of each miRNA by ΔCt value among all detected miRNAs.

Most of the miRNAs were downregulated in plasma samples obtained from MM patients (Figure 1a). The most striking difference of expression was found in miR-223. In addition, members of the miR-17-92a cluster (miR-19b, miR-17, miR-92a, miR-20a and miR-19a) were significantly decreased in MM




Figure 1. Identification of expressed plasma miRNAs in MM. (a) Downregulated miRNAs in MM (open bars). The expression level in the sample was 4-fold lower than that of normal controls (solid bars). Arrows indicate miR-17-92a polycistronic cluster. (b) Upregulated miRNAs in MM (open bars). The expression level in the sample was 4-fold higher than that of normal controls (solid bars).

samples. Although we found several upregulated miRNAs in MM samples, the Ct values were generally low in both MM samples and normal controls (Figure 1b). We therefore focused on downregulation of the miR-17-92a cluster, rather than the single miRNA (that is, miR-223), because the expression of miR-17-92a cluster is essential in the lymphoid ontogeny and measured the expression level of miR-92a in a large series of patients.

Plasma miR-92a level of symptomatic MM

Plasma miR-92a levels were significantly lower in newly diagnosed MM patients ($n = 62$) compared with healthy controls (Student's t -test: $P < 0.0001$); the level of plasma miR-92a in symptomatic MM patients was $< 10\%$ compared with normal subjects (mean \pm standard error 0.1008 ± 0.01899 vs 1.388 ± 0.06993 ; Table 1). Among the MM patients, there were no significant differences in the plasma miR-92a levels, irrespective of MM subtype ($P = 0.4472$) (Figure 2a), light chain type ($P = 0.4413$) (Supplementary Figure 1A) or International Staging System staging ($P = 0.1955$) (Supplementary Figure 1B). The presence of anemia ($P = 0.0990$), bone lesion ($P = 0.6701$), renal damage ($P = 0.4258$) or hypercalcemia ($P = 0.1989$) did not affect plasma miR-92a level at MM diagnosis (Supplementary Figure 2AD, Supplementary Table 1). Plasma miR-92a level was not correlated with beta2 microglobulin elevation ($P = 0.3675$), albumin level ($P = 0.0693$), elevated lactate dehydrogenase ($P = 0.4863$) or performance status ($P = 0.9850$) (Supplementary Table 1).

The receiver operating characteristic curve was generated by comparing the patients' Δ Ct values with those of healthy volunteers. The analysis showed that miR-92a was a good marker of newly diagnosed MM (AUC = 0.9810), indicating 91.94%




Figure 2. Plasma miR-92a values in MM and receiver operating characteristic curve. (a) Plasma miR-92a level (miR-92a/miR-638) in patients with MM at the time of diagnosis. A significant downregulated plasma miR-92a level is notable in MM at diagnosis (MM-Dx) ($P < 0.0001$). No particular difference in plasma miR-92a level is evident among immunoglobulin subtypes, Bence-Jones protein type or non-secretory MM by one-way ANOVA. Bars indicate minimum to maximum plasma miR-92a levels and boxes indicate 95% confidence interval (CI). (b) The cut-off level of plasma miR-92a/miR-638 in all MM at diagnosis is 0.2593. The sensitivity is 91.94% (95% CI: 82.17–97.33%) and specificity is 99.12% (95% CI: 95.17–99.98%).

sensitivity (95% confidence interval: 82.17–97.33%) and 99.12% specificity (95% confidence interval: 95.17–99.98%) when the cut-off levels of plasma miR-92a in MM patients at diagnosis could be achieved (that is, 0.2593) (Figure 2b).

Plasma miR-92a level in the various states of MM

We next compared the plasma miR-92a level in MM patients in various clinical states (Table 1). Patients in CR ($n = 8$) had a significant increase in plasma miR-92a compared with those at diagnosis ($P < 0.0001$), and seven out of the eight patients were normalized (≥ 0.2593 cut-off level). Of the PR patients ($n = 15$), a significant increase in plasma miR-92a was notable ($P < 0.0001$), but these patients still had low plasma miR-92a compared with normal subjects ($P = 0.0033$). Although patients with stable disease ($n = 14$) had a partially normalized plasma miR-92a level, three patients had an extremely low level, similar to those of patients with newly diagnosed MM. In progressive disease patients ($n = 28$), the plasma miR-92a level again downregulated and no significant difference was notable compared with newly diagnosed MM (Figure 3a).

Plasma miR-92a levels of MGUS and SMM patients

We also measured plasma miR-92a levels in 8 patients with SMM and 22 with MGUS (Table 1). Compared with normal subjects, patients with SMM showed no significant differences in plasma miR-92a levels ($P=0.4642$), but they had elevated levels compared with MM patients ($P=0.0496$) (Figure 3b). The plasma miR-92a level was significantly decreased in MGUS patients compared with normal subjects ($P<0.0001$), but they had significantly higher plasma miR-92a levels compared with MM patients ($P=0.0005$). No difference in plasma miR-92a levels was noted between SMM and MGUS patients ($P=0.2959$). The plasma miR-92a levels did not correlate with duration between the time of diagnosis of MGUS and the measurement of levels in this study (data not shown).

miR-92a level in separated lymphocytes

We then compared miR-92a levels in T lymphocytes obtained from healthy subjects ($n=21$) with those of MM patients at diagnosis ($n=6$) or at CR/VGPR status ($n=5$). The miR-92a level in CD4⁺ or CD8⁺ T lymphocytes in MM patients at diagnosis was significantly lower compared with that of healthy subjects (CD4⁺: $P=0.0178$; CD8⁺: $P=0.0092$) (Figure 4a). Comparison of miR-92a of CD4⁺ and CD8⁺ T lymphocytes showed a roughly linear correlation, and most MM patients in CR/VGPR status had an increased level (Figure 4b). Although no apparent correlation was evident in normal subjects, MM patients with low levels of plasma miR-92a had low levels of miR-92a expression in CD4⁺ (Figure 4c) and CD8⁺ T lymphocytes (Figure 4d), and three out of the five MM patients with CR/VGPR had normal levels of plasma and cellular miR-92a.

DISCUSSION

The use of plasma miRNAs as potential biomarkers is a growing research area,^{12–14} and this is the first study to look at plasma miRNAs in MM. Our findings indicate the possible clinical utility of plasma miRNA level in MM patients. The recent introduction of new agents has improved the response rate and survival in patients with MM.²¹ In MM treatment, the decision to start chemotherapy usually depends on the presence of clinical symptoms with high evidence level, so-called CRAB (hypercalcemia, renal failure, anemia, bone lesion) symptoms.²² Moreover, the therapeutic target point in MM patients has been proposed,²³ and practical guidelines for the therapeutic strategy have been helpful in clinical decision-making for MM treatment.^{24,25} However, there are some MM patients for whom the timing and combination of chemotherapy are difficult to decide,²⁶ although high-risk MM patients can be classified.^{27,28} Because, decisions regarding chemotherapy are occasionally difficult in non-secretory or asymptomatic MM patients, a novel diagnostic marker is urgently required, in addition to the conventional diagnostic tool.²¹ In the current study, we demonstrated the downregulation of plasma miR-92a in symptomatic MM patients, irrespective of the presence or absence of renal damage or M-protein, suggesting that the measurement of the plasma miR-92a could be helpful for deciding when to initiate chemotherapy.

Chromosomal abnormalities and molecular alterations in MM cells have been extensively investigated, and some of them are currently incorporated into the risk analysis.^{23,27,29} In addition, pathogenesis of extracellular circumstances, including angiogenesis,³⁰ in MM patients is an important issue not only for understanding the biology of myeloma but therapeutic strategies as well.²¹ In myeloma cells, overexpression of the miR-17-92a has been noted in the transformation from MGUS to MM.¹⁵ Therefore, miR-17-92a expression is thought to correlate with tumor burden in MM patients. In contrast, we found no difference in plasma miR-92a levels between MGUS and SMM patients. Because the plasma miR-92a level was significantly different between patients with SMM




Figure 3. Plasma miR-92a expression in MM at various clinical phases and SMM or MGUS. (a) The downregulated plasma miR-92a level at myeloma diagnosis (MM-Dx) was normalized in CR (MM-CR) and was partially normalized at VGPR (MM-VGPR) or PR (MM-PR) phase. (b) Patients with SMM had a higher plasma miR-92a level than that of symptomatic myeloma ($P=0.0496$), but they had low levels compared with normal subjects. Although some patients with MGUS had low levels of plasma miR-92a, most MGUS patients had plasma miR-92a levels similar to those with SMM. Bars indicate minimum to maximum plasma miR-92a levels and boxes indicate 95% CI.

and symptomatic myeloma, the level of plasma miR-92a level could reflect the pathological condition of patients rather than the tumor burden of myeloma cells in the body. Moreover, normalization of the plasma miR-92a level after obtaining CR suggests that the plasma miR-92a level might serve as an indicator for therapeutic response. The number of treated patients studied was small, however, and further research is needed to clarify this possibility.

Studies have shown that some circulating miRNAs in cancer-bearing patients are tumor-derived,⁷ and thus such miRNAs might be used as biomarkers of cancer.^{12–14} The downregulation of plasma miR-92a has been recognized in patients with hematologic neoplasia, including acute leukemia,^{16,17} non-Hodgkin's lymphoma¹⁸ and hepatocellular carcinoma,³¹ as well as in patients with cardiovascular diseases.³² Because miR-17-92a is essential in the development and ontogeny of the lymphoid system,^{33,34} we examined the correlation between miR-92a levels in separated lymphocytes and plasma. The plasma miR-92a levels was




Figure 4. Cellular miR-92a in CD8⁺ or CD4⁺ lymphocytes in MM and normal subjects. **(a)** The CD4⁺ miR-92a ($P=0.0178$) and CD8⁺ miR-92a ($P=0.0092$) are significantly downregulated. **(b)** Comparison between miR-92a levels in CD4⁺ and CD8⁺ T lymphocytes in normal subjects (closed circles), MM at diagnosis (open squares) and myeloma in CR/VGPR (open triangles), showing a positive correlation. Comparison between plasma miR-92a and the cellular miR-92a of CD4⁺ T lymphocytes **(c)** or CD8⁺ T lymphocytes **(d)** in identical subjects. Myeloma patients with low levels of miR-92a in CD4⁺ T lymphocytes cluster at low levels of plasma miR-92a, and some MM patients with CR/VGPR show normalization of miR-92a levels in plasma, CD4⁺ and CD8⁺ T lymphocytes.

correlated with the miR-92a level in T lymphocytes, especially CD8⁺ lymphocytes. Some MM patients in CR/VGPR showed normalization of the plasma miR-92a level, in combination with upregulation of T-cell miR-92a. A recent study reported that the miR-17-92a cluster was critical for optimal T-lymphocyte co-stimulation via CD28 and was thereby essential for regulatory T function under certain conditions.³⁵ Moreover, it is reported that the type-1-skewing tumor microenvironment induces downregulation of miR-17-92a expression, with decreased levels of miR-17-92a noted in both CD4⁺ and CD8⁺ cells in tumor-bearing mice and in CD4⁺ cells in patients with glioblastoma multiforme.³⁶ Together, these findings suggest that the low level of miR-92a in T lymphocytes may represent dysregulation of immunity and the downregulated plasma miR-92a level in MM patients may reflect the dysfunction of T lymphocytes *in vivo*. In addition to miR-17-92a downregulation, the TaqMan low-density array screening revealed downregulation of miR-223, a regulator of neutrophil proliferation and activation.³⁷ The ultimate downregulation of plasma miR-223 in MM patients might also be related with granulocyte dysfunction.

In conclusion, the plasma miR-92a level may serve as a biomarker for monitoring therapeutic response in MM patients and disease progression in asymptomatic MM patients. The

downregulated plasma miR-92a level may be linked to the expression level of T-cell-derived miR-92a. Although we examined a small number of patients, especially MM patients who had been treated, these initial findings suggest that plasma miR-92a levels in monoclonal gammopathy patients may be a promising parameter not only for determining disease status but also whether further treatment is required.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank C Kobayashi, R Soya-Hamamura and A Hirota for their technical assistance. This work was supported by the Private University Strategic Research Based Support Project: Epigenetics Research Project Aimed at General Cancer Cure Using Epigenetic Targets from the Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan.

AUTHOR CONTRIBUTIONS

SY, KO and JHO designed the study, analyzed the data, interpreted the data and wrote the manuscript; TU and MO performed quantitative PCR analysis of plasma miRNA; KO performed statistical analysis; SY, KO, KS, AI, and SI provided patient samples.

REFERENCES

- 1 Baltimore D, Boldin MP, O'Connell RM, Rao DA, Taganov KD. MicroRNAs: new regulators of immune cell development and function. *Nat Immunol* 2008; **9**: 839-845.
- 2 Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004; **116**: 281-297.
- 3 He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. *Nat Rev Genet* 2004; **5**: 522-531.
- 4 Esquela-Kerscher A, Slack FJ. Oncomirs: microRNAs with a role in cancer. *Nat Rev Cancer* 2006; **6**: 259-269.
- 5 Garzon R, Calin GA, Croce CM. MicroRNAs in cancers. *Annu Rev Med* 2009; **60**: 167-179.
- 6 Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. *J Clin Oncol* 2009; **27**: 5848-5856.
- 7 Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanian EL *et al*. Circulating microRNAs as stable blood-based markers for cancer detection. *Proc Natl Acad Sci USA* 2008; **105**: 10513-10518.
- 8 Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L *et al*. Detection of microRNA expression in human peripheral blood microvesicles. *PLoS One* 2009; **3**: e3694.
- 9 Mathivanan S, Ji H, Simpson R. Exosomes: extracellular organelles important in intracellular communication. *J Proteomics* 2010; **73**: 1907-1920.
- 10 Valadi H, Ekstrom K, Bossios A, Sjöstrand M, Lee JJ, Lötvald JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol* 2007; **9**: 654-659.
- 11 Turchinovich A, Weiz L, Langhinz A, Burwinkel B. Characterization of extracellular circulating microRNA. *Nucleic Acids Res*; e-pub ahead of print, 24 May 2011; doi: 10.1093/nar/gkr254.
- 12 Gilad S, Meiri E, Yogev Y, Benjamin S, Labanony D, Yerushalmin *et al*. Serum microRNAs are promising novel biomarkers. *PLoS One* 2008; **3**: e3148.
- 13 Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K *et al*. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Res* 2008; **18**: 997-1006.
- 14 Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. *Gynecol Oncol* 2009; **112**: 55-59.
- 15 Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D *et al*. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. *Proc Natl Acad Sci USA* 2008; **105**: 12885-12890.
- 16 Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, Ohyashiki K *et al*. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. *PLoS One* 2009; **4**: e5532.
- 17 Ohyashiki JH, Umezu T, Kobayashi C, Hamamura RS, Tanaka M, Kudo M *et al*. Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: *in vivo* assessment of cell to plasma ratio of miR-92a. *BMC Res Notes* 2010; **3**: 347.
- 18 Ohyashiki K, Umezu T, Yoshizawa S, Ito Y, Ohyashiki M, Kawashima H *et al*. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. *PLoS One* 2011; **6**: e16408.
- 19 Zuo Z, Calin GA, de Paula H, Medeiros J, Fernandez MH, Shimizu M *et al*. Circulating miRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. *Blood* 2011; **118**: 413-415.
- 20 Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P *et al*. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. *Leukemia* 2009; **23**: 1716-1730.
- 21 Palumbo A, Anderson K. Multiple myeloma. *New Engl J Med* 2011; **36**: 1046-1060.
- 22 Blad J, Dimopoulos M, Rosiñol L, Kyle RA, Rajkumar SV. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. *J Clin Oncol* 2010; **28**: 690-697.
- 23 Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. *Leukemia* 2009; **23**: 3-9.
- 24 Rajkumar SV, Harousseau J-L, Durie B, Landgren O, Blade J, Merlini G *et al*. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. *Blood* 2011; **117**: 4691-4695.
- 25 Dimopoulos M, Kyle R, Fermand J-P, Rajkumar SV, San Miguel J, Chanan-Khan A *et al*. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 3. *Blood* 2011; **117**: 4701-4705.
- 26 Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G *et al*. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. *Leukemia* 2010; **24**: 1121-1127.
- 27 Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK *et al*. International Myeloma Working Group. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. *Leukemia* 2009; **23**: 2210-2221.
- 28 Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B *et al*. International Myeloma Workshop Consensus Panel 2. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. *Blood* 2011; **117**: 4696-4700.
- 29 Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C *et al*. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. *Blood* 2007; **109**: 3489-3495.
- 30 Podar K, Tai YT, Lin BK, Narsimhan RP, Sattler M, Kijima T *et al*. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. *J Biol Chem* 2002; **277**: 7875-7881.
- 31 Shigoka M, Tsuchida A, Matsudo T, Nagakawa Y, Saito H, Suzuki Y *et al*. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. *Pathol Int* 2010; **60**: 351-357.
- 32 Fichtlscherer S, De Rosa S, Fox H, Schweitz T, Fischer A, Liebetrau C *et al*. Circulating microRNAs in patients with coronary artery disease. *Circulation Res* 2010; **107**: 677-684.
- 33 Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J *et al*. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. *Nat Immunol* 2008; **9**: 405-414.
- 34 Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. *Cell* 2009; **9**: 26-36.
- 35 Jeker L, De Kouchkovsky D, Esensten J, Bluestone J. The miR-17-92 cluster is essential for regulatory T cell function *in vivo*. *J Immunol* 2011; **186**: 168.
- 36 Sasaki K, Kohanbash G, Hoji A, Ueda R, McDonald HA, Reinhart TA *et al*. miR-17-92 expression in differentiated T cells: - implications for cancer immunotherapy. *J Translat Med* 2010; **8**: 17.
- 37 Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O *et al*. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. *Nature* 2008; **451**: 1125-1129.



This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>

Supplementary Information accompanies the paper on Blood Cancer Journal website (<http://www.nature.com/bcj>)

Risk of Japanese carriers of hyperphosphorylated paratarg-7, the first autosomal-dominantly inherited risk factor for hematological neoplasms, to develop monoclonal gammopathy of undetermined significance and multiple myeloma

Sandra Grass,¹ Shinsuke Iida,² Aleksandra Wikowicz,¹ Klaus-Dieter Preuss,¹ Atsushi Inagaki,² Kazuyuki Shimizu,³ Marita Ziepert,⁴ Ryuzo Ueda² and Michael Pfreundschuh^{1,5}

¹Jóse-Carreras-Center for Immuno and Gene Therapy, Department of Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany; ²Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya; ³Nagoya City Midori Municipal Hospital, Nagoya, Japan; ⁴IMISE, Leipzig University, Leipzig, Germany

(Received October 13, 2010/Revised November 22, 2010/Accepted November 29, 2010/Accepted manuscript online December 6, 2010/Article first published online January 25, 2011)

Hyperphosphorylated paratarg-7 (pP-7) is a frequent target of paraproteins in German patients with monoclonal gammopathy of undetermined significance (MGUS)/multiple myeloma (MM). The frequency of MGUS/MM is lower in Japan than in Europe. As pP-7, the first molecularly defined autosomal-dominant risk factor for any hematological neoplasm, is inherited in a dominant fashion, we determined the incidence of the pP-7 carrier state in a Japanese population, and compared the frequency of pP-7-specific paraproteins and the pP-7 carrier state in Japanese and German patients with MGUS/MM. Peripheral blood from 111 Japanese patients with MGUS/MM and 278 healthy blood donors was analyzed for the pP-7 carrier state by isoelectric focusing and for pP-7-specific antibodies by ELISA. The Japanese group was compared with 252 German MGUS/MM patients and 200 healthy controls. Five of 111 (4.5%) Japanese and 35/252 (13.9%) German IgA/IgG MGUS/MM patients had a pP-7-specific paraprotein ($P = 0.009$). The prevalence of healthy pP-7 carriers in the Japanese study group was 1/278 (0.36%), whereas it was 4/200 in the German group ($P = 0.166$). The relative risk for pP-7 carriers developing MGUS/MM had an odds ratio of 13.1 in the Japanese and 7.9 in the German group. In conclusion, the fraction of pP-7 carriers with a pP-7-specific paraprotein is lower among Japanese than in German patients with MGUS/MM, but pP-7 carriers in both ethnic groups have a high risk of developing MGUS/MM. (*Cancer Sci* 2011; 102: 565–568)

Multiple myeloma (MM) is a B-lymphocyte-derived malignancy characterized by a monoclonal proliferation of plasma cells that produce a clonal immunoglobulin. Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic precursor condition commonly preceding MM.⁽¹⁾ Recent studies show that family members of MGUS and MM patients have a two to threefold higher risk of developing MGUS/MM.^(2,3) Environmental influences, chance occurrence, and inherited factors might all contribute to familial clusters. Also, the incidence of MM and the prevalence of MGUS are reportedly two to threefold higher among Black people than White people,^(4–6) and lower in Asians.^(6,7) Until now, the pathogenesis of MGUS/MM has remained obscure. A causal relationship between MGUS/MM and chronic antigenic stimulation has been suggested by the results of several studies,^(8–12) hence the identification of the antigenic stimuli of B-cell neoplasms might be of considerable importance. Antigenic targets of paraproteins

were discovered accidentally due to clinical symptoms caused by the paraprotein (e.g. chronic cold agglutinin disease or cryoglobulinemia⁽¹³⁾ or bleeding disorders⁽¹⁴⁾), because of interference of the paraprotein with laboratory tests ordered for the clinical work-up of the patient (e.g. HIV-1 p24 antigen in an HIV-infected patient with myeloma),⁽¹⁵⁾ and/or by screening paraproteins against pre-defined antigens (e.g. anti-streptolysin, anti-DNA, or anti-IgG⁽¹³⁾). The first systematic studies covering a broad spectrum of potential antigens used serological identification of antigens by expression cloning (SEREX), which allows for the systematic screening of putative antibody–antigen interactions, even if neither the antigen nor the antibody are known.⁽¹⁶⁾ cDNA libraries derived from human testis, lung, and breast cancer, bovine and porcine muscle, and wheat germ were expressed in *Escherichia coli* and investigated by SEREX for reactivity with paraproteins from the sera of 114 patients with MGUS or MM. More than 6×10^8 paraprotein–antigen interactions were probed, resulting in the identification of only four antigens, each recognized by the paraprotein of only one patient.^(17,18) In a complementary approach using a human fetal brain-derived macroarray and IgA or IgG paraprotein-containing sera, the paraproteins of 29 (15.1%) consecutive MGUS and MM patients reacted with paratarg-7 (P-7).⁽¹⁹⁾ Paratarg-7 is identical to STOML2 (stomatin [EPB72]-like), also known as HSPC108 or stomatin-like protein and SLP-2,⁽²⁰⁾ that has also been reported to be expressed in all human tissues and overexpressed^(21,22) in several cancers.⁽²³⁾ Other investigators have reported that P-7 modulates T cell activation,⁽²⁴⁾ and in a recent publication it was claimed that SLP-2 is required for stress-induced mitochondrial hyperfusion.⁽²⁵⁾ In an extension of our earlier study, the high frequency of P-7-specific paraproteins in the sera of MGUS/MM patients (35/252; 14%) was confirmed in a subsequent study.⁽²⁶⁾ Moreover, it was shown that all patients with P-7-specific paraproteins were carriers of a hyperphosphorylated version of the protein (pP-7) and that this hyperphosphorylation is inherited in a dominant fashion.^(26,27) As only 2% of healthy Germans are carriers of pP-7, the pP-7 carrier state is associated with an increased risk (odds ratio, 7.9) to develop MGUS/MM. Thus, pP-7 is the first molecularly defined inherited risk factor known for any hematological neoplasm. Because of the autosomal-dominant inheritance of pP-7, it is of interest to determine the prevalence of the pP-7

⁵To whom correspondence should be addressed.
E-mail: michael.pfreundschuh@uks.eu

carrier state and the frequency of pP-7-specific paraproteins in other ethnic groups. As the incidence of MGUS and MM is lower in Asians than in Europeans,^(6,7) it was the aim of this study to compare a German population with a Japanese population with respect to the prevalence of the pP-7 carrier state and the incidence of P-7-specific paraproteins in MGUS and MM.

Materials and Methods

Patients and controls. This study was approved by the local German ethical review board (Ethikkommission der Ärztekammer des Saarlandes, Saarbrücken, Germany) and the internal review board of Nagoya City University and Nagoya City Midori Municipal Hospital (Nagoya, Japan). Serum samples were taken from 111 Japanese patients with MGUS/MM treated at Nagoya City University Hospital or Nagoya City Midori Municipal Hospital and 252 German patients treated at Saarland University Medical School (Homburg/Saar, Germany). Serum protein electrophoresis identified a monoclonal spike in these samples, which was shown to contain a monoclonal IgA, IgD, or IgG paraprotein by immunofixation. The German control group consisted of 200 healthy employees of Saarland University Medical School and the Japanese control group consisted of 278 Japanese healthy blood donors. "Healthy" was defined as being healthy in the pre-donation medical check-up and having no monoclonal immunoglobulin by serum electrophoresis and immunofixation. In addition, the healthy donors who were identified by isoelectric focusing (IEF) as pP-7 carriers were contacted and they confirmed that they were without any major health problems and explicitly without malignant disease, in particular.

The same criteria were applied in our previous study to the German population of 252 MGUS/MM patients. The German control group was the same as in the previous study. There was no difference with respect to age, gender (all patients), progression to MM, or stage of the disease between patients with a P-7-specific paraprotein. Patients were listed under MGUS if the first blood sample was obtained while they had still MGUS, even if they later progressed into MM. Whenever possible, human materials were obtained during routine diagnostic or therapeutic procedures and stored at -80°C until use.

Western blot sample preparation. For Western blot analyses, blood samples were centrifuged and washed with PBS. The pellet was resuspended in 8 M urea, 0.1 M phosphate, 10 mM Tris-HCl (pH 8.0), and 0.1% NP-40 and incubated at 20°C for 15 min.

Isoelectric focusing for determination of pP-7 carrier state. Blood samples were centrifuged and washed with PBS followed by lysis in lysis buffer containing 8 M urea, 0.1 M NaH_2PO_4 , 0.01 M Tris-HCl, and 0.1% NP40 (15 min, 20°C) and stored at -20°C until use. Equal volumes of sample and loading buffer were mixed. Samples were analysed by IEF on a gel with a fixed pH gradient (pH 3.0–10.0) according to the manufacturer's instructions (Novex pH 3.0–10.0; Invitrogen, Karlsruhe, Germany) followed by an immunoblot screening.

Immunoblot staining. After lysates from whole peripheral blood were separated by IEF or SDS-PAGE under reducing conditions, the proteins were transferred to an Immobilon-P PVDF membrane (Immobilon; Millipore, Eschborn, Germany) by semi-dry blotting. The membrane was blocked overnight at 4°C in TBST/milk buffer (10% [v/v] milk in 10 mM Tris-HCl [pH 7.5], 150 mM NaCl, and 0.1% [v/v] Tween 20), washed and incubated for 1 h at room temperature with serum in TBST (paraprotein-containing serum from patients at a dilution of $1:10^8$ and from controls at a dilution of $1:10^3$). After three washings in TBST, the membranes were incubated for 1 h at room temperature with mouse anti-human IgG-POX antibody (BioRad, Dreieich, Germany) diluted 1:3000 in TBST. The

membranes were then washed in TBST, followed by detection using Pharmacia's ECL (enhanced chemiluminescence) system (General Electric Healthcare, Fairfield, CT, USA).

Paratarg-7 ELISA for detection of paraproteins with specificity to P-7. To determine the antigen specificity of the paraproteins, the P-7 ELISA using full-length recombinant paratarg-7 was carried out as described previously.⁽¹⁹⁾

Results

Thirty-five of 252 (13.9%) paraproteins from the German MGUS/MM patients were shown by ELISA to react with paratarg-7. In contrast, only 5/111 Japanese patients (4.5%) had a paraprotein specific for paratarg-7 (Table 1) and were carriers of pP-7 (Fig. 1). This difference is significant with a *P*-value of 0.009 (chi-square test). The anti-paratarg-7 reactivity of these sera had titres ranging from $1:10^8$ to $1:10^{10}$. None of the sera from healthy controls reacted at a dilution of $\leq 1:10^2$. Lower serum dilutions were not tested because they cause too much background in the P-7 ELISA. As was the case with the German IgG paraproteins with specificity for P-7,⁽¹⁹⁾ all Japanese P-7 reactive IgG paraproteins (4/78) belonged to the IgG₃ subtype, with 4/38 IgG₃ (10.5%) paraproteins displaying this specificity. The prevalence of healthy pP-7 carriers in the healthy Japanese population, as determined by IEF (Fig. 1) followed by immunoblot staining, was lower (1/278 or 0.36%) than in the German (4/200 or 2.0%) population. This is a strong trend but, due to the low prevalence of a pP-7 carrier state in healthy controls, did not reach significance (*P* = 0.166; Fisher's exact test). Nevertheless, the relative risk for pP-7 carriers to develop MGUS/MM is significant in both ethnic groups with an odds ratio of 13.1 (95% confidence interval, 1.5–113.1; *P* = 0.020) in

Table 1. Detection of paratarg-7-specific paraproteins in 252 German and 111 Japanese consecutive patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM)

	MGUS (%)	MM (%)	Total (%)
Japanese patients			
IgA	0/3 (0)	1/22 (4.5)	1/25 (4.0)
IgD	0/0 (0)	0/8 (0)	0/8 (0)
IgG	0/8 (0)	4/70 (5.3)†	4/78 (5.1)†
Total	0/11 (0)	5/100 (5.0)	5/111 (4.5)
German patients			
IgA	2/24 (8.3)	4/21 (19.0)	6/45 (13.3)
IgD	0/0 (0)	0/0 (0)	0/0 (0)
IgG	15/117 (12.8)†	14/90 (15.5)†	29/207 (14.0)†
Total	17/141 (12.1)	18/111 (16.2)	35/252 (13.9)

†All pP-7 reactive IgG paraproteins were of the IgG₃ subclass.




Fig. 1. Western blot analysis after isoelectric focusing of paratarg-7 (P-7) derived from Japanese and German patients with P-7-reactive paraproteins. Bands of whole peripheral blood lysates from two Japanese patients with multiple myeloma (J1, J2) with anti-P-7 paraproteins, one German patient with a P-7-specific paraprotein (G2) and one German patient with a non-P-7-specific paraprotein (G1) migrated differently.